Protalix BioTherapeutics
PLX
33 hedge funds and large institutions have $3.86M invested in Protalix BioTherapeutics in 2019 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 5 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
11% more capital invested
Capital invested by funds: $3.47M → $3.86M (+$387K)
1.62% less ownership
Funds ownership: 7.58% → 5.96% (-1.6%)
8% less funds holding
Funds holding: 36 → 33 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
97% less call options, than puts
Call options by funds: $6K | Put options by funds: $188K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$142K |
| 2 |
MWPCG
Measured Wealth Private Client Group
Portsmouth,
New Hampshire
|
+$17.2K |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$8.16K |
| 4 |
AA
Advisory Alpha
Holland,
Michigan
|
+$2.25K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$1.58K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$777K |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$31K |
| 3 |
Jane Street
New York
|
-$24K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$11.1K |
| 5 |
Invesco
Atlanta,
Georgia
|
-$11K |
PLX Hedge Fund Activity: Q1 2019 in Review
33 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q1 2019, worth a combined $3.86M — up 11% from $3.47M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of PLX and 2 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 6 added.
The largest buyer was Renaissance Technologies, adding an estimated $142K. The largest seller was Opaleye Management, exiting entirely with an estimated $777K sold.
- 33 institutional investors held Protalix BioTherapeutics (PLX) as of Q1 2019, down from 36 in Q4 2018.
- Funds reported $3.86M of Protalix BioTherapeutics stock for Q1 2019, up 11% quarter-over-quarter.
- 2 funds opened new Protalix BioTherapeutics positions in Q1 2019 and 5 closed out, a net change of -3 holders.
- The largest Protalix BioTherapeutics buyer in Q1 2019 was Renaissance Technologies, an estimated $142K added.
- The largest Protalix BioTherapeutics seller in Q1 2019 was Opaleye Management, an estimated $777K sold.
Based on aggregated 13F filings for Q1 2019.